Extract

To evaluate the efficacy of SR31747 given at 75 or 125mg per day versus placebo in androgen prostate cancer patient without distant metastases with Time to Clinical progression as main objective and PSA parameters, Tumor response, survival , safety,Tumor-related symptoms deterioration Quality of Life, PK analysis as secondary objectives

Inclusion criteria

• Prostatic Neoplasm

Country

• Australia
• Belgium
• Canada
• Chile
• Czech Republic
• France
• Italy
• Mexico
• Netherlands
• Poland
• Portugal
• Spain
• United Kingdom

Links

• ictrp
• nct